A Study To Compare the Effect of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes

Novartis

Status and phase

Completed

Phase 3

Conditions

Diabetes Mellitus, Type 2

Treatments

Drug: Vildagliptin

Study type

Interventional

Funder types

Industry

Identifiers

NCT00351832

CLAF237A1303

Details and patient eligibility

About

This study is not being conducted in the United States. Vildagliptin is an oral antidiabetic agent. This 12-week clinical study is to evaluate the effect of vildagliptin 50mg qd, 50mg bid or 100mg qd compared to placebo in patients with type 2 diabetes.

Sex

All

Ages

20+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Diagnosis of type 2 diabetes
Patients who have been placed on dietary therapy/exercise therapy without achievement of glycemic control
Outpatients

Exclusion criteria

Type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of diabetes
Significant cardiovascular disease
Significant diabetic complications

Other protocol-defined inclusion/exclusion criteria may apply